Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 187 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dapagliflozin 10 mg Clear all
Terminated Phase 2 Interventional Results available

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

NCT05516498
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 5:47 AM EDT
Completed No phase listed Observational

Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data

NCT03078049
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
11,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 4 Interventional Results available

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

NCT04792190
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dapagliflozin, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Portland, Maine • Detroit, Michigan • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

NCT02460978
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo for dapagliflozin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
47
States / cities
Concord, California • Fresno, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 4 Interventional Results available

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

NCT02433678
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
dapagliflozin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

NCT02681094
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Saraland, Alabama • Fresno, California • Harbor City, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 14, 2026, 5:47 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

NCT07273838
View directory record Official record
Conditions
Heart Failure, Acute Kidney Injury
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Not applicable Interventional Results available

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

NCT02777073
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Victoza, Placebo, Dapagliflozin 10mg Tab
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

NCT03619213
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
6,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
66
States / cities
Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

NCT01646320
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching with Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
26
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

NCT02551874
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 14, 2026, 5:47 AM EDT
Completed No phase listed Observational

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

NCT02695082
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
539,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 14, 2026, 5:47 AM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 5:47 AM EDT
Recruiting Phase 4 Interventional

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

NCT06140537
View directory record Official record
Conditions
Kidney Transplant; Complications, Vascular Diseases, Diabetes
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

NCT02419612
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Dapagliflozin, Glimepiride, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

NCT00643851
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 14, 2026, 5:47 AM EDT
Recruiting Phase 3 Interventional

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060
View directory record Official record
Conditions
Heart Failure
Interventions
Baxdrostat and dapagliflozin, Placebo and dapagliflozin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
11,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
198
States / cities
Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 176 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 4 Interventional Results available

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

NCT02981069
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 14, 2026, 5:47 AM EDT
Enrolling by invitation Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:47 AM EDT
Not listed Phase 4 Interventional

Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes

NCT02372955
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
dapagliflozin, glimpiride
Drug
Lead sponsor
Gulf Regional Research & Educational Services, LLC
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 14, 2026, 5:47 AM EDT
Not listed No phase listed Observational

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 14, 2026, 5:47 AM EDT
Completed Phase 2 Interventional

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

NCT00162305
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BMS-512148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 14, 2026, 5:47 AM EDT
Recruiting Phase 3 Interventional

SGLT2i, Pioglitazone, and Ketone Production in T1D

NCT07056699
View directory record Official record
Conditions
Type1diabetes
Interventions
Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 14, 2026, 5:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 5:47 AM EDT